



Veeva Systems Earns Top Honors from *Forbes* and Deloitte Among Other Accolades

Veeva Recognized as a Fastest Growing Software Company and Best Place to Work

BARCELONA, Spain — 22 March 2016 — Veeva Systems (NYSE: VEEV), a leading provider of industry cloud solutions for life sciences, received several prestigious industry awards for its innovation, product excellence, and customer success. The company was ranked one of the fastest growing software companies in Deloitte's 2015 Technology Fast 500™ and appeared in *Forbes* as a best software company to work. Additionally, [Veeva CRM Suggestions](#) was selected as a pharmaceutical marketing venture to watch by *MedAdNews* and [Veeva OpenData](#) was recognized as one of the most innovative products by *PM360*.

"It's an honor to be recognized for our innovation in industry cloud, exceptional company culture, and dedication to customer success," said Peter Gassner, Veeva founder and CEO. "We continue to grow quickly, fueled by focusing on the customer and delivering mission-critical products that keep our customers a step ahead."

Veeva delivers industry cloud software solutions to help life sciences companies achieve their most pressing strategic objectives – bringing drugs to market faster and more efficiently, better market and sell, and improve compliance with government regulations.

Forbes Lists Veeva a 'Best Software Company to Work'

Veeva was listed in *Forbes* magazine as a best software company to work for in 2015. The ranking was based on analysis of third-party ratings of global software companies featured in *Software Magazine's* Software 500 list.

Deloitte Names Veeva to 2015 Technology Fast 500

With revenue growth of 621% from 2011 to 2014, Veeva was ranked 139 in Deloitte's 2015 Technology Fast 500 survey of North America's fastest-growing technology, media, telecommunications, life sciences, and energy technology companies. Veeva also recently announced its fiscal [2016 results](#), demonstrating again a unique combination of high growth and profitability.

Veeva OpenData Lauded as One of the 'Most Innovative Products' by *PM360*

Veeva OpenData was recognized as one of the most innovative products for its new approach to life sciences customer reference data by *PM360*, a leading life sciences industry publication. Available in [35 countries](#) and counting, companies can rely on a single vendor for all major markets with Veeva OpenData. Priced by the record – with a defined-per country maximum – organizations now have a fair and predictable cost of ownership, which is a marked change from the current practice of being charged multiple times to use the same data across teams and departments.

MedAdNews Selected Veeva CRM Suggestions as a Pharmaceutical Marketing Venture to Watch

Veeva CRM Suggestions was named as a pharmaceutical marketing innovation to watch by *MedAdNews* for its game-changing capability to engage customers. Veeva CRM Suggestions leverages the power of data science to deliver a better, more coordinated customer experience by offering recommendations to sales reps on the best action and right channel for the next customer interaction.

Additional Information

Stay updated on the latest Veeva news on LinkedIn: [linkedin.com/company/veeva-systems](https://www.linkedin.com/company/veeva-systems)

Follow @veevasystems on Twitter: twitter.com/veevasystems

Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 400 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's filing on Form 10-Q for the period ended October 31, 2015. This is available on the company's website at www.veeva.com under the Investors section and on the SEC's website at www.sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

###

Contact:

Sue Glanville / Cate Bonthuys

Veeva Systems Inc.

sue@catalystcomms.co.uk / cate@catalystcomms.co.uk

+44 (0) 7715 817589 / +44 (0) 7746 546773

Amy Farrell

Finn Partners

617-366-7149

amy.farrell@finnpartners.com